The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

Abstract

Anti-PD-1-based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients' microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16 ribosomal RNA gene sequencing, metagenomic shotgun sequencing, and quantitative polymerase chain reaction for selected bacteria. A significant association was observed between commensal microbial composition and clinical response. Bacterial species more abundant in responders included ,, and Reconstitution of germ-free mice with fecal material from responding patients could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti-PD-L1 therapy. Our results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients.

Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets

“…A study inspected the composition of baseline stool samples from 42 patients with metastatic melanoma, divided into 2 groups: responders and non-responders (similar characteristics). An association between certain bacterial species in the host gut flora and clinical response was seen in this study [57].…”

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

“…The microbiota is emerging as a determinant of responses to various anticancer therapies, including immunotherapy 122–125 . Virtually nothing is known, however, about the role of the microbiome in antiangiogenic therapy and vice versa.…”

Anti-PD1 in the wonder-gut-land

“…Gajewski's group (University of Chicago, IL, USA) reported the analysis of 38 fecal pre-treatment samples from metastatic melanoma patients treated with anti-PD1 [9]. This analysis, based on 16S rRNA sequencing, shotgun metagenomic and quantitative PCR, identified many bacterial species that predicted a favorable response to the therapy (as analyzed by Recist1.1 criteria).…”